It’s Bittersweet: The Tumorigenic Potential of Glycosylation

Karen Abbott and Susan Bellis discuss how to detect and block tumorigenic glycosylation signatures to diagnose and treat cancer.

The Scientist Creative Services Team in collaboration with Vector Laboratories
Nov 9, 2021

LIVE Webinar

Monday, December 6, 2021
3:00 - 4:30 PM Eastern Time

Register Now

Early cancer detection is a key determinant of patient survival, but scientists struggle to identify reliable biomarkers and diagnostic tools. Researchers recently discovered cancer-specific glycosylation signatures that promote tumor progression. Because protein glycosylation controls cellular behaviors such as cell adhesion and migration, altered glycosylation states render cancer cells more invasive. In this webinar, brought to you by Vector Laboratories, Karen Abbott and Susan Bellis will discuss how cancer cells modify glycosylation pathways to survive, and how to target tumor-specific glycans for early cancer detection, prognosis, and therapeutic development.

Topics to be covered

  • Tools and technologies to detect glycan biomarkers
  • How cancer-induced receptor glycosylation activates tumorigenic pathways
  • The therapeutic potential of tumor-selective glycans

Register Now

Meet the Speakers:

Karen Abbott, PhD
Associate Professor
Department of Translational Medicine
Herbert Wertheim College of Medicine
Florida International University

Susan L. Bellis, PhD
Professor
Department of Cell, Developmental, and Integrative Biology
University of Alabama at Birmingham


Sponsored By